SCHEMBL208442

SCHEMBL208442

CC(C)(C)OC(=O)N[C@@H]1CN(C=O)CC[C@@H]1NC(=O)c1cc2ccc(Cl)cc2cn1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.42
USP30 Q70CQ3 3/20 0.38
EIF2AK4 Q9P2K8 1/20 0.38
ANO1 Q5XXA6 1/20 0.37
CHRNA7 P36544 2/20 0.35
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
PYGL P06737 1/20 0.35
CCR1 P32246 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
JAK3 P52333 1/20 0.35
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265643 0.84 F10 (0.47) F10USP30EIF2AK4ANO1
SCHEMBL4265640 0.84 F10 (0.47) F10USP30EIF2AK4ANO1
SCHEMBL4083820 0.78 F10 (0.65) F10
SCHEMBL2703699 0.77 F10 (0.70) F10
Hydrochloric Acid SCHEMBL207831 0.77 F10 (0.69) F10
Hydrochloric Acid SCHEMBL207830 0.77 F10 (0.69) F10
SCHEMBL207795 0.77 NPC1 (0.39) F10USP30EIF2AK4CCR1
SCHEMBL12056214 0.76 F10 (0.56) F10
SCHEMBL3312651 0.75 ATF4 (0.46) F10EIF2AK4
SCHEMBL210138 0.75 CCR1 (0.39) EIF2AK4CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 F10 15/4885USP30 4666/4885EIF2AK4 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.